Skip to content
Screener

Kymera Therapeutics KYMR Finance Lease Liabilities

Finance Lease Liabilities at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$0-100%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$0—

Other financials

Income statement

See full
Revenue$65.0M+466%
Operating income-$75.6M+10.6%
Net income-$61.2M+20.1%
EPS (diluted)-$0.62+34.7%

Balance sheet

See full
Cash & equivalents$124.5M-62.9%
Total debt$80.1M-8.5%
Total equity$1.5B+55.4%
Total assets$1.6B+45.5%

Cash flow

See full
Operating cash flow-$54.1M+9.7%
CapEx$473.0K-31.9%
Free cash flow-$54.5M+10.0%

Valuation

See full
Market cap$8.68B+199%
Enterprise value$8.63B+225%
P/S82.6×+17.8×

Profitability

See full
Operating margin-333.5%-114pp
Net margin-285.3%-99.7pp
FCF margin-226.6%-84.9pp

Returns & leverage

See full
Return on equity-24.2%-5.2pp
Debt / equity0.1×0.0×
Current ratio10.3×+2.0×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.

The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:15 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333849
Line itemJune 30,2026December 31,2025
Non-current liabilities
Deferred revenue, net of current portion—11,440
Operating lease liabilities, net of current portion64,02267,034
Finance lease liabilities, net of current portion8401,462
Total liabilities$136,188$163,148
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025——
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2026 and December 31, 2025, 82,788,253 and 81,323,532 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively88

Item 1. Financial Statements.

FAQ

What is Kymera Therapeutics's finance lease liabilities?
Kymera Therapeutics (KYMR) reported finance lease liabilities of $840K in Q2 2026.
How has Kymera Therapeutics's finance lease liabilities changed year-over-year?
Kymera Therapeutics's finance lease liabilities decreased by 62.0% year-over-year, from $2.21M to $840K.
What is the long-term trend for Kymera Therapeutics's finance lease liabilities?
Over 5 years (2020 to 2025), Kymera Therapeutics's finance lease liabilities has grown at a 19.3% compound annual growth rate (CAGR), from $604K to $1.46M.
What does finance lease liabilities mean?
Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.

Ask your AI about Kymera Therapeutics's finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude